Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate
| العنوان: | Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate |
|---|---|
| المؤلفون: | Pei Yi Yap, Peter G. Parsons, Glen M. Boyle, Benedict Panizza, Jason K. Cullen, Natasa Broit, Catherine M. E. Barnett |
| المصدر: | Investigational New Drugs. 37:1-8 |
| بيانات النشر: | Springer Science and Business Media LLC, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Male, 0301 basic medicine, Programmed cell death, Apoptosis, Mice, SCID, Nod, Mice, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Mice, Inbred NOD, Tumor Cells, Cultured, Animals, Humans, Medicine, Pharmacology (medical), Survival rate, Cell Proliferation, Pharmacology, Mice, Inbred BALB C, business.industry, medicine.disease, Xenograft Model Antitumor Assays, Head and neck squamous-cell carcinoma, In vitro, Tongue Neoplasms, Tigilanol tiglate, 030104 developmental biology, Neutrophil Infiltration, Oncology, chemistry, Cell culture, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, Cancer research, Immunohistochemistry, Diterpenes, business |
| الوصف: | Summary The five-year survival rate for patients with head and neck squamous cell carcinoma (HNSCC) has remained at ~50% for the past 30 years despite advances in treatment. Tigilanol tiglate (TT, also known as EBC-46) is a novel diterpene ester that induces cell death in HNSCC in vitro and in mouse models, and has recently completed Phase I human clinical trials. The aim of this study was to optimise efficacy of TT treatment by altering different administration parameters. The tongue SCC cell line (SCC-15) was identified as the line with the lowest efficacy to treatment. Subcutaneous xenografts of SCC-15 cells were grown in BALB/c Foxn1nu and NOD/SCID mice and treated with intratumoral injection of 30 μg TT or a vehicle only control (40% propylene glycol (PG)). Greater efficacy of TT treatment was found in the BALB/c Foxn1nu mice compared to NOD/SCID mice. Immunohistochemical analysis indicated a potential role of the host’s innate immune system in this difference, specifically neutrophil infiltration. Neither fractionated doses of TT nor the use of a different excipiant led to significantly increased efficacy. This study confirmed that TT in 40% PG given intratumorally as a single bolus dose was the most efficacious treatment for a tongue SCC mouse model. |
| تدمد: | 1573-0646 0167-6997 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e9273562f91d23aba0306d776eeb27f https://doi.org/10.1007/s10637-018-0604-y |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....4e9273562f91d23aba0306d776eeb27f |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 15730646 01676997 |
|---|